Results 41 to 50 of about 218,137 (295)
Polish Journal of Pathology, 2021 Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin +4 more
doaj +1 more source
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression [PDF]
Frontiers in Immunology, 2019 With the recent approvals for the application of monoclonal antibodies that target the well-characterized immune checkpoints, immune therapy shows great potential against both solid and hematologic tumors. The use of these therapeutic monoclonal antibodies elicits inspiring clinical results with durable objective responses and improvements in overall ...
Xiangfeng Shen +5 more
openaire +3 more sources
BMC Pulmonary Medicine, 2021 Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents ...
Masanori Harada +11 more
doaj +1 more source
Role of Programmed Death‐Ligand 1 in Cancer
The FASEB Journal, 2019 Programmed death‐1 (PD‐1) is an immunoregulatory receptor on cytotoxic T cells that suppresses the immune system upon interaction with its two ligands, programmed death ligand‐1 (PD‐L1) and programmed death ligand‐2 (PD‐L2). Programmed death‐ligand 1 (PD‐L1), previously known as “CD279”, is made up of 268 amino acids with a crystal structure.
Tina Link +8 more
openaire +1 more source
Journal of Thoracic Oncology, 2022 Programmed death-ligand 1 (PD-L1) copy number gains may be predictive of clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number variations in tumor resection and bronchoscopy biopsies and its relationship with PD-L1 tumor cell staining and inflammatory gene expression.PD-L1 gene copy number and mRNA expression were ...
Savreet Aujla +10 more
openaire +3 more sources
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis [PDF]
, 2014 INTRODUCTION: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to eradicate invading pathogens and increased susceptibility to secondary infections.
Andriani C Patera +13 more
core +2 more sources
Zhongliu Fangzhi Yanjiu, 2023 Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS.
DENG Changgang +5 more
doaj +1 more source
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab [PDF]
, 2016 Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration.
Caponnetto, Salvatore +11 more
core +1 more source
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma [PDF]
Asian Pacific Journal of Cancer Prevention, 2019 In this era of developing targeted therapies and immunotherapies as a treatment for renal cell carcinoma (RCC), Programmed death ligand 1 (PDL1) as a novel biomarker for RCC is analysed in our study. About 90% of all renal cancers are Renal Cell Carcinoma. Most cases are diagnosed incidentally. 17% of cases are advanced at the time of diagnosis.
Chandrasekaran, Deepika +3 more
openaire +2 more sources
Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer [PDF]
, 2017 Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable.
Babu, Sunil +4 more
core +1 more source